耳穴贴压预防COVID-19疫苗接种后免疫接种不良事件:多中心三臂盲法随机对照试验的研究方案
本研究为随机、多中心、三臂、单盲对照试验,计划纳入不少于360名受试者,随机分为耳穴贴压组、假耳穴贴压组和等待列表组。干预于注射后立即进行,每日4至5次,持续5天。主要结局为报告任何免疫接种不良事件及注射部位局部疼痛者的质量与数量评估,次要结局包括头痛、肌肉和(或)关节痛、疲劳、恶心、呕吐、腹泻等。
要点
- 干预每日4至5次、持续5天,结局在基线及注射后1、3、5、7、14天评估。
- 主要结局为报告任何免疫接种不良事件者及报告注射部位局部疼痛者的质量与数量评估。
核心结论
- 该试验结果将有助于明确耳穴贴压疗法在预防和缓解COVID-19疫苗接种后总体及特定免疫接种不良事件方面的价值。
研究设计与样本
- 研究设计为随机、多中心、三臂对照、单盲试验。
- 计划纳入不少于360名符合纳入标准的受试者,随机分配至耳穴贴压组、假耳穴贴压组和等待列表组。
- 受试者在医疗机构被招募入组并随机分配,进行注射后观察。
- 干预于注射后立即进行,每日4至5次,持续5天。
- 采用意向性分析和符合方案集分析,显著性水平定为5%。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要临床结局为报告任何免疫接种不良事件者及报告注射部位局部疼痛者的质量与数量评估。
- 次要结局涉及头痛、肌肉和(或)关节痛、疲劳、恶心、呕吐、腹泻及其他潜在事件。
- 所有结局在基线及注射后1、3、5、7、14天评估。
- 试验注册于中国临床试验注册中心(ChiCTR),注册号ChiCTR2100043210,注册日期2021年2月8日。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some pain, fatigue, and gastrointestinal adverse events were observed in potential association with injection of COVID-19 vaccines, while there was no preventive intervention for it. We aim to investigate the efficacy of auricular acupressure (AA) therapy in preventing and relieving AEFI after injection of COVID-19 vaccine. METHODS: The study design is a randomized, multicentre, three-arm controlled, single-blind trial. Participants meeting the inclusion criteria will be advertised and enrolled and assigned in the medical institutions randomly for post-injection observation. No less than 360 participants will be randomized into one of three groups: auricular acupressure group, sham auricular acupressure group, and wait-list group. Interventions will be performed immediately and will happen 4 to 5 times per day for 5 days. The primary clinical outcomes will be quality and quantity evaluation among participants who reported any AEFI and who reported local pain at injection site. Secondary outcomes will concern headache, muscle and (or) joint pain, fatigue, nausea, vomiting, diarrhoea, and other potential events. All the outcomes will be assessed at baseline and 1, 3, 5, 7, and 14 days after the injection. Both intention-to-treat and per-protocol analyses will be performed, with significance level determined as 5%. DISCUSSION: Results of this trial will help to clarify the value of auricular acupressure therapy in preventing and relieving overall and certain adverse events following immunization after injection of COVID-19 vaccine. TRIAL REGISTRATION: China Clinical Trial Registry (ChiCTR) ( ChiCTR2100043210 ). Registered on 8 February, 2021.
引用
- Fu Q, Xie H, Zhou L, et al. Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trial. Trials. 2021. PMID: 34838110. doi:10.1186/s13063-021-05837-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。